Saudi Arabia transfers 8% of Aramco to PIF portfolio, SPA reports-March 2024-www.financetom.com

Saudi Arabia transfers 8% of Aramco to PIF portfolio, SPA reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Saudi Arabia transfers 8% of Aramco to PIF portfolio, SPA reports

Mar 7, 2024 5:24 AM

DUBAI, March 7 (Reuters) - Saudi Arabia has transferred

8% of state oil giant Aramco's total shares to a

portfolio owned by the country's sovereign wealth fund PIF,

state news agency SPA reported on Thursday.

Previous page： AMD chief says company ready to pay 15% tax on AI chip shipments to China Next page： AMD chief says company ready to pay 15% tax on AI chip shipments to China

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

AMD chief says company ready to pay 15% tax on AI chip shipments to China

Mar 10, 2026

SAN FRANCISCO, Dec 4 (Reuters) - Advanced Micro Devices ( AMD ) CEO Lisa Su on Thursday said the company has licenses to ship some of its MI 308 chips to China and is prepared to pay a 15% tax to the U.S. government if it ships them. Su made the remarks at a conference held by technology publication Wired...

AMD chief says company ready to pay 15% tax on AI chip shipments to China

Mar 10, 2026

Belden Insider Sold Shares Worth $306,480, According to a Recent SEC Filing

Mar 10, 2026

01:22 PM EST, 12/04/2025 (MT Newswires) -- Leah Tate, Senior Vice President, Human Resources, on December 03, 2025, sold 2,554 shares in Belden (BDC) for $306,480. Following the Form 4 filing with the SEC, Tate has control over a total of 27,835 common shares of the company, with 27,835 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/913142/000119312525307844/xslF345X05/ownership.xml Price: 120.46, Change: +0.36, Percent...

Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment

Mar 10, 2026

The U.S. Food and Drug Administration (FDA) on Wednesday approved Axogen Inc.’s Biologics License Application for Avance, an acellular nerve scaffold for adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated...